Awaiting development: Guidance and quality standards

Showing 241 to 250 of 362

Guidance and quality standards awaiting development
Title	Type
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]	Technology appraisal guidance
Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]	Technology appraisal guidance
Ravulizumab for treating primary IgA nephropathy [ID6703]	Technology appraisal guidance
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]	Technology appraisal guidance
Reinforcement of a permanent stoma with synthetic or biological mesh to prevent a parastomal hernia	HealthTech guidance
Remdesivir for treating COVID 19 [ID3808]	Technology appraisal guidance
Remibrutinib for treating chronic inducible urticaria inadequately controlled by H1-antihistamines [ID6742]	Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]	Technology appraisal guidance
Retatrutide for managing overweight and obesity [ID6644]	Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]	Technology appraisal guidance